Please login to the form below
Healthcare terms - T
A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W |
Healthcare Glossary
A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W |
Healthcare terms - T
- Tactical planning
- Tagging
- Target audience
- Target publications
- Tariffs
- Technical efficiency (pharmacoeconomics)
- Telesales
- Terms and conditions of purchase
- Terms and conditions of sale
- Territory
- Territory management
- Test marketing
- Testimonials
- Therapy area
- Tonal bias
- Tone of the media
- Top-of-mind awareness (TOMA)
- Toxicity
- Trade advertising
- Trade allowance
- Trade barriers
- Trade publications
- Trademark
- Transfer price
- Treatment Investigational New Drug (IND)
- Treatment trials
- Treatment trials
- Trend analysis
- Trial endpoint
- Trial stage
Subscribe to our email news alerts
Featured jobs
- Country Manager, Healthcare Communications Agency, Germany
-
Highly competitive salary
- Sanofi halts recruitment for trials assessing MS treatment
- bluebird bio reveals plans to launch two gene therapies
- ONS data reveals significant decrease in COVID-19 antibodies
- UK government’s ‘science superpower’ ambitions to fail without clear plan, Lords committee warns
- AstraZeneca and Daiichi Sankyo receive FDA approval for lung cancer drug
- Bayer’s Nubeqa receives FDA approval to treat metastatic prostate cancer
- WHO releases interim statement on COVID-19 vaccination for children and adolescents
- Novartis reports death of two patients treated with Zolgensma
- The impact of COVID-19 on the fight against AMR
- NHS bowel cancer checks reach record-high following death of Dame Deborah James
- Environment: where does the pharmaceutical industry stand?
- Moderna’s Omicron booster receives MHRA approval
- AstraZeneca and Daiichi Sankyo receive FDA approval for lung cancer drug
- Achieving communication excellence by targeting the right channel at the right time
- Environment: where does the pharmaceutical industry stand?
- FDA approves Incyte’s Pemazyre as first targeted drug for bile duct cancer
- Novartis reports death of two patients treated with Zolgensma
- Pfizer, Mylan move ahead with generics merger and spin-out
PMHub
Healthcare Media Europe – HME Ltd
HME are an innovative and technology enabled agency offering our clients over 35+ years of knowledge and expertise in delivering...
